Mark Fishman
Director/Board Member bei BEAM THERAPEUTICS INC.
Vermögen: 561 911 $ am 31.03.2024
Profil
Mark C.
Fishman is currently the Lead Independent Director at Beam Therapeutics, Inc. He is also a Director at Aditum Bio Fund 1 LP, Versanis Bio, Inc., Teres Bio, Inc., Anteris Bio, Inc., and The General Hospital Corp.
Additionally, he serves as a Trustee-Emeritus at The Children's Hospital of Philadelphia.
In his former positions, Dr. Fishman was the Chairman of Novartis Institute for Functional Genomics, Inc. and Semma Therapeutics, Inc. He also served as a Director at Novartis International Pharmaceutical Ltd.
and Geneception, Inc. Furthermore, he was a Member-Executive Board at Novartis AG and the Founding President of Novartis Institutes for Biomedical Research, Inc. He was also the Founding Director of the Cardiovascular Research Center and a Professor at Harvard Medical School.
Dr. Fishman received his undergraduate degree from Yale University in 1972 and his doctorate from Harvard Medical School in 1976.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
BEAM THERAPEUTICS, INC.
0,02% | 06.06.2023 | 17 007 ( 0,02% ) | 561 911 $ | 31.03.2024 |
Aktive Positionen von Mark Fishman
| Unternehmen | Position | Beginn |
|---|---|---|
| BEAM THERAPEUTICS INC. | Director/Board Member | 01.05.2018 |
The Children's Hospital of Philadelphia
 The Children's Hospital of Philadelphia Hospital/Nursing ManagementHealth Services The Children's Hospital of Philadelphia provides health care services. It specializes in pediatrics, research, fetal surgery, pediatric oncology, pediatric cardiology and cardiothoracic surgery, thoracic insufficiency syndrome, and pediatric airway disorders and transplants. The company was founded by Francis West Lewis in 1855 and is headquartered in Philadelphia, PA. | Director/Board Member | - |
Anteris Bio, Inc.
 Anteris Bio, Inc. Pharmaceuticals: MajorHealth Technology Anteris Bio, Inc. develops therapies for the treatment of renal disease. The company is based in Oakland, CA. The CEO of the company is Ilan Zipkin. | Director/Board Member | - |
Versanis Bio, Inc.
 Versanis Bio, Inc. BiotechnologyHealth Technology Part of Eli Lilly & Co., Versanis Bio, Inc. is a clinical-stage biopharmaceutical company. The private company is based in New York, NY. The company was founded by Lloyd Klickstein. Mark E. Pruzanski has been the CEO of the company since 2021. Versanis Bio was acquired by Eli Lilly & Co. on August 14, 2023 for $1,925 million. | Director/Board Member | - |
Aditum Bio Fund 1 LP
 Aditum Bio Fund 1 LP Investment ManagersFinance Aditum Bio Fund 1 LP specializes in acquiring and developing pharmaceutical assets. The company is headquartered in San Mateo, CA. | Director/Board Member | 01.02.2019 |
The General Hospital Corp.
 The General Hospital Corp. Hospital/Nursing ManagementHealth Services The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
Teres Bio, Inc.
 Teres Bio, Inc. Pharmaceuticals: MajorHealth Technology Teres Bio, Inc. operates as a clinical stage life sciences company. It translates discoveries in inflammatory pathways into novel, topical therapies for atopic dermatitis and plaque psoriasis skin diseases. The company is headquartered in Oakland, CA. | Director/Board Member | - |
Ehemalige bekannte Positionen von Mark Fishman
| Unternehmen | Position | Ende |
|---|---|---|
Semma Therapeutics, Inc.
 Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | Chairman | 01.01.2019 |
| NOVARTIS AG | Corporate Officer/Principal | 01.03.2016 |
| ░░░░░░░░ ░░░░░░░░░░ ░░░ ░░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
| ░░░ ░░░░░░ ░░░░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Ausbildung von Mark Fishman
| Yale University | Undergraduate Degree |
| Harvard Medical School | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| NOVARTIS AG | Health Technology |
| BEAM THERAPEUTICS INC. | Health Technology |
| Private Unternehmen | 12 |
|---|---|
The General Hospital Corp.
The General Hospital Corp. Hospital/Nursing ManagementHealth Services The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA. | Health Services |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Commercial Services |
Novartis Institute for Functional Genomics, Inc.
 Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Commercial Services |
The Marine Biological Laboratory
 The Marine Biological Laboratory Miscellaneous Commercial ServicesCommercial Services The Marine Biological Laboratory provides research and educational services. It offers a range of courses, workshops, conferences, and internships, discovery-based education programs and courses. The firm s a private marine laboratory, supporting scientists and staff working in such fields as cell and developmental biology, ecology, microbiology, molecular evolution, global infectious disease, neurobiology, and sensory physiology. The company was founded in 1888 and is headquartered in Woods Hole, MA. | Commercial Services |
Novartis International Pharmaceutical Ltd.
 Novartis International Pharmaceutical Ltd. Pharmaceuticals: MajorHealth Technology Novartis International Pharmaceutical Ltd. manufactures and distributes pharmaceutical products. The company is headquartered in Ireland. | Health Technology |
The Children's Hospital of Philadelphia
The Children's Hospital of Philadelphia Hospital/Nursing ManagementHealth Services The Children's Hospital of Philadelphia provides health care services. It specializes in pediatrics, research, fetal surgery, pediatric oncology, pediatric cardiology and cardiothoracic surgery, thoracic insufficiency syndrome, and pediatric airway disorders and transplants. The company was founded by Francis West Lewis in 1855 and is headquartered in Philadelphia, PA. | Health Services |
Aditum Bio Fund 1 LP
Aditum Bio Fund 1 LP Investment ManagersFinance Aditum Bio Fund 1 LP specializes in acquiring and developing pharmaceutical assets. The company is headquartered in San Mateo, CA. | Finance |
Geneception, Inc.
 Geneception, Inc. BiotechnologyHealth Technology Geneception, Inc. provides healthcare services. The company is headquartered in Cambridge, MA. | Health Technology |
Versanis Bio, Inc.
Versanis Bio, Inc. BiotechnologyHealth Technology Part of Eli Lilly & Co., Versanis Bio, Inc. is a clinical-stage biopharmaceutical company. The private company is based in New York, NY. The company was founded by Lloyd Klickstein. Mark E. Pruzanski has been the CEO of the company since 2021. Versanis Bio was acquired by Eli Lilly & Co. on August 14, 2023 for $1,925 million. | Health Technology |
Teres Bio, Inc.
Teres Bio, Inc. Pharmaceuticals: MajorHealth Technology Teres Bio, Inc. operates as a clinical stage life sciences company. It translates discoveries in inflammatory pathways into novel, topical therapies for atopic dermatitis and plaque psoriasis skin diseases. The company is headquartered in Oakland, CA. | Health Technology |
Anteris Bio, Inc.
Anteris Bio, Inc. Pharmaceuticals: MajorHealth Technology Anteris Bio, Inc. develops therapies for the treatment of renal disease. The company is based in Oakland, CA. The CEO of the company is Ilan Zipkin. | Health Technology |
Semma Therapeutics, Inc.
Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | Health Technology |
